Publications by authors named "Luca Licata"

Claim this Profile
T
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.
Luca Licata, Marco Mariani, Giulia Viale, Rebecca Dent, Sara M Tolaney

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.
Justin M Balko, Luca Licata, Xiao Qian Wang, Matteo Dugo, Chiun-Sheng Huang

NPJ Breast Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.
Yeon Hee Park, Giampaolo Bianchini, Javier Cortés, Luca Licata, María Vidal

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer.
Luca Licata, Maria Vittoria Dieci, Carmine De Angelis, Caterina Marchiò, Federica Miglietta

Cancer Treat Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023.
Marco Mariani, Giulia Viale, Barbara Galbardi, Luca Licata, Carlo Bosi

JAMA Netw Open· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
Luca Licata, Rita De Sanctis, Andrea Vingiani, Deborah Cosentini, Monica Iorfida

Breast Cancer Res Treat· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors for Breast Cancer Treatment: A Review.
Stefania Morganti, Antonio Marra, Carmine De Angelis, Angela Toss, Luca Licata

JAMA Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.
Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Luca Licata

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Carlo Bosi, Áron Bartha, Barbara Galbardi, Giulia Notini, Matteo M Naldini, Luca Licata

Eur J Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
Luca Licata, Marco Barreca, Barbara Galbardi, Matteo Dugo, Giulia Viale

Br J Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer.
Luca Licata, Marco Mariani, Federico Rossari, Giulia Viale, Giulia Notini

Breast· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor

NPJ Breast Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group.
Luca Licata, Deborah Cosentini, Rita De Sanctis, Monica Iorfida, Elena Rota Caremoli

Front Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, Luca Gianni

Nat Rev Clin Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
Giulia Viale, Luca Licata, Lorenzo Sica, Stefania Zambelli, Patrizia Zucchinelli

Oncologist· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
Raffaella Palumbo, Luca Licata, Federico Sottotetti, Barbara Tagliaferri, Emma Pozzi

Oncol Res Treat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience.
Raffaella Palumbo, Federico Sottotetti, Erica Quaquarini, Anna Gambaro, Antonella Ferzi, Luca Licata

Ther Adv Med Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring response of advanced Merkel cell carcinoma to Avelumab with F-FDG PET/CT.
Cecilia Vellani, Daniela D'Ambrosio, Luca Licata, Ilaria Vacchieri, Antonio Bernardo

Eur J Nucl Med Mol Imaging· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis